Kissei Discussing Rovatirelin Path After Mixed Phase III Results
Pooled Analysis Shows Significance In SCD
Executive Summary
Japanese firm in discussions with regulator as high-need novel therapy for spinocerebellar degeneration misses endpoint but shows promise in pooled analysis.